GU Oncologist @IUCancerCenter; Medicine Mom; Passion for MedEd
Indianapolis, IN
Joined July 2019
- Tweets46
- Following202
- Followers285
- Likes81
Jennifer King retweeted
In 1974, the survival rate for testicular cancer was just 5%. Today, thanks to the groundbreaking work of Lawrence Einhorn, MD, at @IUCancerCenter, that number has soared to more than 95%. Join us in celebrating 50 years of transformative research: ow.ly/Fvto50Tpzw6.
Jennifer King retweeted
Patients with relapsed germ cell tumors with progressive brain metastases are curable with multimodal therapy which includes high-dose chemotherapy + SCT. Aggressive and efficient management of these patients can alter outcomes. @JenniferKingMD @IUCancerCenter @IUHemOnc #ASCO24
Jennifer King retweeted
🚀 Brilliant poster presentation by @rebeccahassoun on longitudinal evaluation of ctNA as a prognostic biomarker to detect minimal
residual disease in testicular cancer #ASCO24 ‼️
@ASCO @ASCOTECAG @OncoAlert
Our amazing 1st yr fellow @AhmedBilalKhal2 presenting pts with stage 1 NSGCT on active surveillance w/ RP only relapse treated with chemo vs RPLND. Important features of pts carefully selected for RPLND:
☑️Normal tumor markers
☑️RP LNs <3cm
☑️ Longer duration prior to relapse
Milwaukee is cold and it was snowing this morning 🥶😳, but still thrilled to attend my first #cgea conference. Grateful for support and mentorship @IUCancerCenter from @JenSchwartzIUSM for guiding and encouraging #meded passion
Jennifer King retweeted
Pegfilgrastim in metastatic germ-cell tumor treatment with bleomycin shows no increased risk for lung toxicity. @IndianaUniv
@ASCO #GU24 @OncoAlert @urotoday @DrChoueiri @yekeduz_emre @AmandaNizamMD @TiansterZhang @crisbergerot @CParkMD @cdanicas @FabioSchutz78 @OncBrothers @NazliDizman @IMG_Oncologists @OncLive @uromigos
Jennifer King retweeted
Safety of pegfilgastrim in patients with germ cell tumors treated with bleomycin-containing regimens. No increased risk of lung toxicity! @IUCancerCenter @JenniferKingMD @IUSMDeptMed @rebeccahassoun
Jennifer King retweeted
@rebeccahassoun presenting initial results for ctDNA monitoring in patients with stage II/III non-seminomatous GCT. Need to validate data in future cohorts @IUCancerCenter #GU24 @IUSMDeptMed @JenniferKingMD @SalousTareq @ClintCaryMD @IUuro @DrJohnSfakianos
Jennifer King retweeted
🧬 ctDNA making progress to evaluate cancer recurrence for Stage II and Stage III non seminoma germ cell tumors #GU24
@CParkMD @nabiladra @IUCancerCenter @JenniferKingMD @ClintCaryMD @rebeccahassoun @SalousTareq – at San Francisco, CA
🧬🩸ctDNA might just be the new frontier in tracking NSGCT.
🧬🩸🧬In those with Stage II-III, it's showing promise as a better tool than serum markers to predict outcomes.
Rebecca Hassoun, MD @IUCancerCenter
@ASCO #GU24 @OncoAlert @urotoday @DrChoueiri @yekeduz_emre @AmandaNizamMD @TiansterZhang @crisbergerot @CParkMD @cdanicas @FabioSchutz78 @OncBrothers @NazliDizman @IMG_Oncologists @kidneycan @KidneyCancer @OncLive @uromigos
Our superstar @IUHemOnc fellow @AhmedBilalKhal2 and his work on BMI and outcomes in GCT patient treated with HDCT 👏 @IUCancerCenter @nabiladra #GU24
Jennifer King retweeted
@IUCancerCenter GU oncology group at #GU24 Proud to be part of this great team! @JenniferKingMD @SalousTareq @ClintCaryMD @rebeccahassoun @IUSMDeptMed @IUHemOnc @IUuro
Jennifer King retweeted
We have more work to share at @asco -GU. Tomorrow, 1/27 8-10am join us at TIP Poster Session C: TPS492 Poster Board M13. Study led by Michael B. Atkins, MD of @LombardiCancer
meetings.asco.org/abstracts-… @DrKarieRuncie
Jennifer King retweeted
GU post doc @rebeccahassoun from @IUCancerCenter presenting real world data for predictors of PSA response to PSMA Lu-177 in metastatic castration resistant prostate cancer. @IUSMDeptMed @JenniferKingMD @SalousTareq #GU24
Jennifer King retweeted
We are very excited to welcome our new class of fellows matched @IUHemOnc
Congratulations! We are THRILLED to have you join us and looking forward to welcoming all of you! @IUCancerCenter
Jennifer King retweeted
Teratoma in the primary tumor or in post-chemotherapy residual non-retroperitoneal disease is not associated with inferior survival in metastatic non-seminomatous germ cell tumors. ja.ma/3FQe4GP
Jennifer King retweeted
🎤 #OncologyGrandRounds: Resection of all residual masses after chemotherapy remains the standard of care in testicular nonseminomas ➡️ fal.cn/3Apz9 @TimGilliganMD
Jennifer King retweeted
Kudos to @nabiladra for leading and organizing @IUCancerCenter 30th anniversary ASCO review 🙌🏼
Jennifer King retweeted
Join us this Saturday July 15 for the 30th Anniversary of the IU Review & Interpretation of the ASCO Meeting. We have a great speaker lineup and special features! iu.cloud-cme.com/course/cour…
@TarahBallinger @JenniferKingMD @anita_turk @gdurm @IUCancerCenter @IUSMDeptMed
Jennifer King retweeted
Teratoma in the primary tumor site was associated with a higher incidence of teratoma in residual nonretroperitoneal (non–RP) disease post-chemotherapy, according to findings from a retrospective study. @JenniferKingMD @IUMedSchool #OncClub #tscsm ow.ly/1Y7V50OYxmG
Jennifer King retweeted
Maintenance oral etoposide after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors. #BeyondTheAbstract with @nabiladra @IUCancerCenter. #ReadNow on UroToday > bit.ly/3zZ8Fu3 #TesticularCancer @FadiTaza @RafatAbonour @DrM_AbuZaid
